SG/CALL/ELI LILLY & CO/1000/0.1/19.09.25 | Market Closed - Börse Stuttgart 07:59:58 25/06/2024 BST | ||
| 9.88 EUR | +2.17% |
|
| Current month | +42.57% | ||
| 1 month | +41.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 9.88 | +2.17% |
| 24/06/24 | 9.67 | +1.47% |
| 21/06/24 | 9.53 | -2.36% |
| 20/06/24 | 9.76 | 0.00% |
| 19/06/24 | 9.76 | +0.93% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92YX |
| ISIN | DE000SU92YX4 |
| Date issued | 29/02/2024 |
| Strike | 1,000 $ |
| Maturity | 19/09/2025 (451 Days) |
| Parity | 10 : 1 |
| Emission price | 5.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.88 € |
|---|---|
| Lowest since issue | 4.4 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
